The ERK5 pathway in BRAFV600E melanoma cells plays a role in development of acquired resistance to dabrafenib but not vemurafenib
Sign Up to like & getrecommendations! Published in 2024 at "FEBS Letters"
DOI: 10.1002/1873-3468.14960
Abstract: Malignant melanoma, an aggressive skin cancer with a poor prognosis, frequently features BRAFV600E mutation resulting in activation of the MAPK pathway and melanocyte proliferation and survival. BRAFV600E inhibitors like vemurafenib and dabrafenib have enhanced patient… read more here.
Keywords: vemurafenib; resistance; brafv600e melanoma; dabrafenib ... See more keywords
Dabrafenib in BRAFV600E mutant pilocytic astrocytoma
Sign Up to like & getrecommendations! Published in 2020 at "Child's Nervous System"
DOI: 10.1007/s00381-020-04527-4
Abstract: Dear Editor: We read the report on “Dabrafenib in BRAFV600E mutant pilocytic astrocytoma (PA) in a pediatric patient” with a great interest [1]. Mustansir et al. concluded that “We report a case of successful treatment… read more here.
Keywords: pilocytic astrocytoma; dabrafenib; mutant pilocytic; dabrafenib brafv600e ... See more keywords
Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature.
Sign Up to like & getrecommendations! Published in 2020 at "Current problems in cancer"
DOI: 10.1016/j.currproblcancer.2020.100668
Abstract: INTRODUCTION Anaplastic thyroid carcinoma (ATC) is a highly aggressive, undifferentiated rare tumor. Median overall survival is usually between 8 and10 months, with a 1-year survival rate of 20%. Conventional anthracycline based chemotherapy regimens demonstrate low… read more here.
Keywords: anaplastic thyroid; dabrafenib; case; rechallenge ... See more keywords
Simultaneous quantification of dabrafenib, hydroxy-dabrafenib and trametinib in human plasma by liquid chromatography-tandem mass spectrometry.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of pharmaceutical and biomedical analysis"
DOI: 10.1016/j.jpba.2020.113718
Abstract: A new liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous quantification of dabrafenib (DAB), its main metabolite hydroxy-dabrafenib (OHD) and trametinib (TRA) in human plasma has been developed and validated. After addition of internal… read more here.
Keywords: chromatography tandem; plasma; dabrafenib; mass spectrometry ... See more keywords
Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy.
Sign Up to like & getrecommendations! Published in 2021 at "Toxicology and applied pharmacology"
DOI: 10.1016/j.taap.2021.115797
Abstract: Dabrafenib is a BRAF inhibitor used in combination treatment of malignant melanoma and non-small cell lung carcinoma. In this study, we aimed to characterize its interactions with cytochrome P450 (CYP) isoenzymes and ATP-binding cassette (ABC)… read more here.
Keywords: combination; inhibits abcg2; dabrafenib inhibits; dabrafenib ... See more keywords
BIOM-03. DABRAFENIB AND STEROIDS FOR THE TREATMENT OF ERDHEIM-CHESTER DISEASE WITH EXTENSIVE CENTRAL NERVOUS SYSTEM INVOLVEMENT
Sign Up to like & getrecommendations! Published in 2024 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noae165.0076
Abstract: Erdheim-Chester disease (ECD) is an exceedingly rare non–Langerhans cell CD68+ CD1a- S100- histiocytic multi-organ disease. Diagnosis of ECD is often delayed due to non-specific radiographic findings and heterogeneous lesional tissue. Increasingly, the role of genomic… read more here.
Keywords: disease; treatment; chester disease; dabrafenib ... See more keywords
Dabrafenib- and trametinib-associated glomerular toxicity
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000028485
Abstract: Abstract Rationale: Combined treatment with dabrafenib, a B-RAF inhibitor, and trametinib, a mitogen-activated protein kinase inhibitor, is an effective option for patients with metastatic melanoma. A few cases of acute kidney injury associated with tubulointerstitial… read more here.
Keywords: dabrafenib; kidney; dabrafenib trametinib; metastatic melanoma ... See more keywords
Sustained Clinical Remission of BRAF V600E-Mutated Langerhans Cell Histiocytosis With Multiorgan Involvement in an Infant Treated With Dabrafenib
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000003014
Abstract: Background: Above 50% of LCH cases show BRAF-mutations, which can be targeted by dabrafenib in refractory disease. Observations: Here, we report on a patient with neonatal multisystem, BRAF-mutated LCH refractory to conventional treatment with vinblastine… read more here.
Keywords: braf; dabrafenib; sustained clinical; clinical remission ... See more keywords
Dabrafenib Is a Safe and Effective Therapy in Relapsed/Refractory Classical Hairy Cell Leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-137531
Abstract: BACKGROUND: Hairy cell leukemia (HCL) is a rare indolent B-cell lymphoproliferative disorder. The BRAF V600E mutation was shown to be the underlying genetic driver for the vast majority of classical HCL (HCLc) cases and treatment… read more here.
Keywords: response; dabrafenib; treatment; therapy ... See more keywords
Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600–Mutant Low-Grade Glioma
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.01000
Abstract: PURPOSE BRAF V600 mutations occur in many childhood cancers, including approximately 20% of low-grade gliomas (LGGs). Here, we describe a phase I/II study establishing pediatric dosing and pharmacokinetics of trametinib with or without dabrafenib, as… read more here.
Keywords: safety; braf v600; combination; trametinib ... See more keywords
Dabrafenib Induced Pancreatitis: A Rare Event During RAI- Refractory Treatment of Metastatic Papillary Thyroid Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Journal of the Endocrine Society"
DOI: 10.1210/jendso/bvab048.1814
Abstract: Dabrafenib, a BRAF selective tyrosine kinase inhibitor (TKI) has been associated with pancreatitis alone, and in combination with trametinib (a MEK pathway inhibitor). We report a case of dabrafenib induced acute pancreatitis in a patient… read more here.
Keywords: pancreatitis; treatment; dabrafenib; thyroid cancer ... See more keywords